B. Metzler seel. Sohn & Co. AG Takes Position in Guardant Health, Inc. $GH

B. Metzler seel. Sohn & Co. AG purchased a new stake in shares of Guardant Health, Inc. (NASDAQ:GH) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 8,918 shares of the company’s stock, valued at approximately $911,000.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Emerald Advisers LLC increased its position in shares of Guardant Health by 24.8% during the 3rd quarter. Emerald Advisers LLC now owns 873,203 shares of the company’s stock valued at $54,558,000 after purchasing an additional 173,281 shares during the last quarter. Knights of Columbus Asset Advisors LLC purchased a new stake in shares of Guardant Health during the 3rd quarter valued at about $1,554,000. Universal Beteiligungs und Servicegesellschaft mbH increased its holdings in Guardant Health by 54.4% in the 3rd quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 301,449 shares of the company’s stock worth $18,835,000 after acquiring an additional 106,263 shares in the last quarter. Erste Asset Management GmbH increased its holdings in Guardant Health by 10.4% in the 3rd quarter. Erste Asset Management GmbH now owns 705,217 shares of the company’s stock worth $43,716,000 after acquiring an additional 66,617 shares in the last quarter. Finally, Segall Bryant & Hamill LLC increased its holdings in Guardant Health by 57.8% in the 3rd quarter. Segall Bryant & Hamill LLC now owns 305,147 shares of the company’s stock worth $19,066,000 after acquiring an additional 111,822 shares in the last quarter. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Guardant Health Stock Performance

Guardant Health stock opened at $88.91 on Monday. The firm has a 50 day moving average of $90.98 and a 200 day moving average of $95.76. The firm has a market capitalization of $11.66 billion, a price-to-earnings ratio of -26.86 and a beta of 1.64. Guardant Health, Inc. has a 12-month low of $36.36 and a 12-month high of $120.74.

Guardant Health (NASDAQ:GH) last announced its quarterly earnings data on Thursday, February 19th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.07). The business had revenue of $281.27 million for the quarter, compared to analyst estimates of $269.74 million. During the same period in the prior year, the business posted ($0.62) earnings per share. Guardant Health’s quarterly revenue was up 39.4% on a year-over-year basis. On average, analysts predict that Guardant Health, Inc. will post -2.87 EPS for the current year.

Insider Activity at Guardant Health

In other Guardant Health news, insider Terilyn J. Monroe sold 3,832 shares of the stock in a transaction that occurred on Monday, April 6th. The shares were sold at an average price of $92.68, for a total transaction of $355,149.76. Following the completion of the sale, the insider directly owned 20,990 shares of the company’s stock, valued at $1,945,353.20. This trade represents a 15.44% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Musa Tariq sold 348 shares of the stock in a transaction that occurred on Wednesday, March 18th. The shares were sold at an average price of $88.09, for a total transaction of $30,655.32. Following the sale, the director directly owned 8,394 shares of the company’s stock, valued at approximately $739,427.46. This trade represents a 3.98% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 8,596 shares of company stock valued at $775,767. Corporate insiders own 6.10% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on GH shares. BTIG Research increased their target price on shares of Guardant Health from $140.00 to $145.00 and gave the stock a “buy” rating in a report on Friday, February 20th. Wells Fargo & Company increased their target price on shares of Guardant Health from $120.00 to $125.00 and gave the stock an “overweight” rating in a report on Friday, February 20th. Weiss Ratings reissued a “sell (d-)” rating on shares of Guardant Health in a report on Tuesday, April 21st. JPMorgan Chase & Co. increased their target price on shares of Guardant Health from $120.00 to $130.00 and gave the stock an “overweight” rating in a report on Friday, February 20th. Finally, Barclays reduced their target price on shares of Guardant Health from $130.00 to $115.00 and set an “overweight” rating for the company in a report on Tuesday, April 14th. Twenty research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Guardant Health has a consensus rating of “Moderate Buy” and a consensus price target of $125.20.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.